

Press Release

Stockholm, Sweden, November 5, 2024

Mendus to present multiple abstracts at ASH 2024, including survival update of ADVANCE II trial with lead program vididencel in AML

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it will present updated survival data from the ongoing ADVANCE II trial with vididencel in acute myeloid leukemia (AML) at the upcoming ASH 2024 conference.

Mendus will present updated survival data from the ADVANCE II trial, a Phase 2 trial addressing AML patients with measurable residual disease, during the 66th annual meeting of the American Society for Hematology (ASH), held December 7-10, 2024 (ASH 2024). The data will be presented on Sunday, December 8, at 6.00 pm PST. Mendus will publish a press release summarizing the data on Monday, December 9 at 8.00 am CET.

Additionally, Mendus will present abstracts based on preclinical data supporting the combination of vididencel with the current AML therapy backbone drugs azacitidine and venetoclax and exploring the use of vididencel in chronic myeloid leukemia at ASH 2024.

Abstracts have been published online on the ASH website [ASH Annual Meeting Abstracts - Hematology.org](https://www.aschociety.org/abstracts) at 9.00 am ET on November 5, 2024. Please find below the details of the abstracts to be presented by Mendus and academic collaborators:

Publication Number: 2875; Title: Active Immunotherapy with Vididencel As Maintenance Treatment in MRD+ AML Patients in CR1 Results in Strong Anti-Tumor Immune Responses and Durable Long-Term Survival in Patients with an Immune Competent Immune Profile; Session Name: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II; Session Date: Sunday, December 8, 2024; Presentation Time: 6.00–8.00 pm PST; Location: San Diego Convention Center, Halls G-H

Publication Number: 2062; Title: Vididencel, a Leukemia-Derived Dendritic Cell Vaccine, Acts Synergistically with Azacitidine/Venetoclax Treatment in a Preclinical AML Model; Session Name: 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster I; Session Date: Saturday, December 7, 2024; Presentation Time: 5.30-7.30pm; Location: San Diego Convention Center, Halls G-H

Publication Number: 4522; Title: In Vitro interactions between TKIs and Leukemic-Derived Dendritic Cells As Potential Combination Therapy for Chronic Myeloid Leukemia; Session Name: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III; Session Date: Monday, December 9, 2024; Presentation Time: 6.00-8.00 pm PST; Location: San Diego Convention Center, Halls G-H

For more information, please contact:

Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com

About Mendus AB (publ)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <https://www.mendus.com/>